儿童与成人混合表型急性白血病的治疗:系统综述与荟萃分析
该系统综述与荟萃分析检索七个数据库至2017年6月,纳入97篇报告共1499例MPAL患者,其中1351例可定量分析。荟萃分析显示,与ALL方案相比,AML诱导方案获得完全缓解的可能性更低(WHO2008 OR=0.33,95%CI 0.18-0.58;EGIL OR=0.18,95%CI 0.08-0.40),且ALL方案起始治疗的总生存更优。
要点
- AML诱导方案较ALL方案获得完全缓解的可能性更低(WHO2008 OR=0.33,95%CI 0.18-0.58;EGIL OR=0.18,95%CI 0.08-0.40)。
- 荟萃分析显示ALL方案起始治疗的总生存优于AML方案(WHO2008 OR=0.45,95%CI 0.26-0.77;EGIL OR=0.43,95%CI 0.24-0.78)。
- 患者水平多变量分析显示,仅混合方案起始治疗者预后更差(HR=2.11,95%CI 1.30-3.43)。
核心结论
- 使用任一种MPAL定义,ALL方案与较高的初始缓解率相关,且在长期生存方面至少等同于更强的AML方案。
- 需要前瞻性试验为这一异质性疾病建立统一治疗方法。
研究设计与样本
- 系统综述与荟萃分析,检索七个数据库从建库至2017年6月,无年龄或语言限制。
- 纳入报告了足够治疗细节的初诊MPAL研究,MPAL按EGIL或WHO2008标准分类。
- 共纳入来自33个国家的97篇报告,1499例独特患者,其中1351例有足够细节进行终点定量分析。
- 对完全缓解和总生存终点进行了荟萃分析及患者水平汇编病例系列的多变量分析。
主要发现
- 荟萃分析显示AML诱导较ALL方案获得完全缓解的可能性更低(WHO2008 OR=0.33,95%CI 0.18-0.58;EGIL OR=0.18,95%CI 0.08-0.40)。
- 患者水平数据多变量分析支持AML诱导疗效较差(对比ALL:OR=0.45,95%CI 0.27-0.77)。
- 荟萃分析发现ALL方案起始治疗的总生存优于AML方案(WHO2008 OR=0.45,95%CI 0.26-0.77;EGIL OR=0.43,95%CI 0.24-0.78)。
- 患者水平数据多变量分析显示仅混合方案起始治疗者预后更差(HR=2.11,95%CI 1.30-3.43)。
- MPAL定义不影响各终点内的趋势,且对结局的预测相似。
关键数值与推荐
- 完全缓解:AML诱导对比ALL方案,WHO2008 OR=0.33(95%CI 0.18-0.58),EGIL OR=0.18(95%CI 0.08-0.40)。
- 总生存:ALL对比AML方案起始治疗,WHO2008 OR=0.45(95%CI 0.26-0.77),EGIL OR=0.43(95%CI 0.24-0.78)。
- 患者水平多变量分析:AML诱导对比ALL方案完全缓解OR=0.45(95%CI 0.27-0.77)。
- 患者水平多变量分析:混合方案起始治疗对比其他,总生存HR=2.11(95%CI 1.30-3.43)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The rarity of mixed-phenotype acute leukemia (MPAL) has resulted in diffuse literature consisting of small case series, thus precluding a consensus treatment approach. We conducted a meta-analysis and systematic review to investigate the association of treatment type (acute lymphoblastic leukemia [ALL], acute myeloid leukemia [AML], or "hybrid" regimens), disease response, and survival. We searched seven databases from inception through June 2017 without age or language restriction. Included studies reported sufficient treatment detail for de novo MPAL classified according to the well-established European Group for Immunological Characterization of Acute Leukemias (EGIL) or World Health Organization (WHO2008) criteria. Meta-analyses and multivariable analyses of a patient-level compiled case series were performed for the endpoints of complete remission (CR) and overall survival (OS). We identified 97 reports from 33 countries meeting criteria, resulting in 1,499 unique patients with data, of whom 1,351 had sufficient detail for quantitative analysis of the study endpoints. Using either definition of MPAL, meta-analyses revealed that AML induction was less likely to achieve a CR as compared to ALL regimens, (WHO2008 odds ratio [OR] = 0.33, 95% confidence interval [95% CI] 0.18-0.58; EGIL, OR = 0.18, 95% CI 0.08-0.40). Multivariable analysis of the patient-level data supported poorer efficacy for AML induction (versus ALL: OR = 0.45 95% CI 0.27-0.77). Meta-analyses similarly found better OS for those beginning with ALL versus AML therapy (WHO2008 OR = 0.45, 95% CI 0.26-0.77; EGIL, OR = 0.43, 95% CI 0.24-0.78), but multivariable analysis of patient-level data showed only those starting with hybrid therapy fared worse (hazard ratio [HR] = 2.11, 95% CI 1.30-3.43). MPAL definition did not impact trends within each endpoint and were similarly predictive of outcome. Using either definition of MPAL, ALL-therapy is associated with higher initial remission rates for MPAL and is at least equivalent to more intensive AML therapy for long-term survival. Prospective trials are needed to establish a uniform approach to this heterogeneous disease.
引用
- Maruffi M, Sposto R, Oberley MJ, et al. Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis. Leukemia. 2018. PMID: 29550836. doi:10.1038/s41375-018-0058-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。